GR-389988   Click here for help

GtoPdb Ligand ID: 10257

Synonyms: Ex. 3-15 [US9174986B2] | GR389988 | GZ389988 | GZ389988A
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GR-389988 (a.k.a. GZ389988) is a neurotrophic receptor tyrosine kinase/Trk inhibitor that was developed by Genzyme. It blocks nerve growth factor (NGF)/Trk pathway activation. The chemical structure is claimed in Genzyme's patent US9174986B2 for utility in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and especially for the management of osteoarthritis and osteoarthritis pain. GR-389988 also inhibits c-FMS, the cellular receptor for colony stimulating factor-1 (CSF-1).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 102.24
Molecular weight 470.21
XLogP 4.1
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1cc(ccc1OCc1ccc(cc1)OC)Cn1c(N)nc2c1ncc(c2)c1cnn(c1)C
Isomeric SMILES COc1cc(ccc1OCc1ccc(cc1)OC)Cn1c(N)nc2c1ncc(c2)c1cnn(c1)C
InChI InChI=1S/C26H26N6O3/c1-31-15-20(13-29-31)19-11-22-25(28-12-19)32(26(27)30-22)14-18-6-9-23(24(10-18)34-3)35-16-17-4-7-21(33-2)8-5-17/h4-13,15H,14,16H2,1-3H3,(H2,27,30)
No information available.
Summary of Clinical Use Click here for help
GZ389988 has completed Phase 2 proof-of-concept evaluation in patients with knee osteoarthritis (see NCT02845271), for which results were published in 2019 [2]. As of August 2021, there were no active studies of GZ389988 listed on
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02845271 Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee Phase 2 Interventional Sanofi In this study a single intra-articular injection of GZ389988A reduced pain and improved function compared to placebo, in participants with painful knee osteoarthritis, with an acceptable safety profile. 2